<table>
<thead>
<tr>
<th>Date</th>
<th>Signatures</th>
<th>Ownership</th>
<th>Company Name</th>
<th>QI</th>
<th>Assets</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/3/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2/2/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3/3/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4/4/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5/5/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6/6/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7/7/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8/8/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9/9/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10/10/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11/11/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12/12/2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1/1/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2/2/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3/3/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4/4/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5/5/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6/6/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7/7/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8/8/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9/9/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10/10/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11/11/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12/12/2024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Index
Pharmacological Reviews
Volume 39
1987

Accidents, risk of, benzodiazepine use, 308
Acepromazine, share of world market (table), 326
Acetaminophen, absolute versus normalized clearance, 7
Acetylhydrolase, acetyltansferase and, inactivation, platelet-activating factor, 101
Acetyltransferase, biosynthesis of platelet-activating factor, 100
Adenylate cyclase, β-receptors, 84
Adrenoceptors, distribution, 50
Aggression, abuse liability of benzodiazepines, 317
Aging
benzodiazepine use, 297
interview studies of prevalence of use (table), 366
learning and recall, benzodiazepines, 307
prevalence of use in hospitals (table), 366
prevalence of use in long-term care institutions (table), 368
twelve-month prevalence of use, antianxiety/sedative agents (table), 365
Agonists
comparisons, 277
dose, benzodiazepines, 276
opioid receptor, potency, 199
response and concentration (fig.), 200
mixtures, 216
potency in GPI and MVD preparations (table), 210
removal from bathing fluid, 218
tissue receptor density (fig.), 201
Albumin, receptor model, 24
Alcohol, drivers detained while driving intoxicated (table), 311
Alcoholics
outpatients, benzodiazepines, 266
use of benzodiazepines, 375
Aldosterone, blood versus plasma clearance, 5
Allergy, skin diseases, platelet-activating factor, 117
[D-Ala²]Met-enkephalinamide, opioid receptor binding (fig.), 224
Alprazolam
psychomotor performance
elderly subjects (table), 298
insomnia (table), 296
repeated doses (table), 293
share of world market (table), 326
Anamnesia
benzodiazepines, 300
retrograde, 304
Amobarbital
abuse liability of benzodiazepines, 259
share of world market (table), 326
AMP, cyclic
catecholamine action on smooth muscle, 59, 79
β-receptor activation, 84
Anaphylaxis
cardiac, 114
platelet-activating factor, 111
Anesthetics, hepatic clearance, model predictions, 19
Antagonists
competitive antagonism, 203
dose, benzodiazepines, 275
opioid receptor, 202
Anxiety
antianxiety/sedative drugs
duration of regular daily use (table), 356
twelve-month prevalence of use (table), 345
benzodiazepines, 294
psychomotor performance (table), 295
recall, 305
Aorta, catecholamine action, smooth muscle, 71, 78, 83
Arteries
basilar, 70
carotid, 73, 78
cerebral, 69
coronary, 68, 78, 82, 86
ear, 69, 70, 77
mesenteric, 67, 71, 77, 86
potassium efflux, 74
pulmonary, 73
renal, 68, 71
saphenous, 69
tail, 69, 71, 78
Aspirin, platelet-activating factor, 105
Assays
opioid receptor
autoradiographic techniques, 232
bioassay, 199, 205, 207
methodologies, 228
radioreceptor, 219
Asthma, platelet-activating factor, 111
Atrial natriuretic factor, cyclic GMP synthesis and function, 183
Australia
drug sales of benzodiazepines, 329
physician survey, 335
Automobile accidents
benzodiazepine use, 308
fatally injured victims, 314
nonfatally injured victims, 313
Autoradiography
grain density (fig.), 233
opioid receptor, 232
μ receptors (fig.), 233
Barbiturates
compared to diazepam, 264
reversing withdrawal, benzodiazepines, 268
Behavior, social, benzodiazepines, 316
Benzodiazepines
abuse liability, 254
adverse behavioral consequences, 290
change in prescribed daily dose (table), 359
comparisons, 271
coroners' reports, 382
drug utilization review studies, 331
duration of treatment, 271, 276
Benzodiazepines (continued)
epidemiological studies, 310
factors predisposing to dependence, 283
fatalities associated with use, 383
high doses and psychomotor performance (table), 292
hospital admissions, 381
hospital cases, 378
human studies, physiological dependence, 278
intensive care unit admissions, 382
interview and questionnaire studies, 279
misuse and recreational use, 371
mortality, 385
patients' strategies if drug withdrawn (table), 363
patterns of use, 356
placebo-controlled studies, 280
drug-related, 329
psychomotor performance, 290
psychotropic drug purchases, 333
regional and hospital prescription sales (table), 332
regional and other surveys of consumption (table), 349
reinforcing behavior, 263
reviews of dependence, 285
shorter-acting, discontinuation, 282
surveys of consumption, 344
therapeutic doses (table), 291
trankulizer use (fig.), 325
twelve-month prevalence of use (table), 345
withdrawal, 270
Bilirubin, blood versus plasma clearance, 7
Blood
free fraction, hepatic extraction (fig.), 22
versus plasma clearance, 5
Blood flow, model predictions, hepatic clearance (fig.), 17
Braquet, P., T. Y. Shen, L. Touqui, and B. Vargaftig. B. Perspectives on platelet-activating factor research, 97
Bromazepam, share of world market (table), 326
Bülbring, Edith, and Tadeo Tomita. Catecholamine action on smooth muscle, 49
Buspirone, alcohol dependence, 265
Calcium
arteries and arterioles, 67
catecholamine action on smooth muscle, 59, 61, 62
channel blocking agents, 137
Canada, drug sales of benzodiazepines, 329
Cancer, chemotherapy, PAF-related phospholipids, 119
Cardiac output
absolute versus normalized clearance, 7
clearance and first-pass effect, 9
hepatic clearance, model predictions, 18
Catecholamine, action on smooth muscle, 49, 52, 79
CDP-choline cholinophosphotransferase, biosynthesis of platelet-activating factor, 102
Central nervous system, platelet-activating factor, 117
Centrifugation, blood versus plasma clearance, 7
CGS-8216, plasma corticosterone, 274
Chemotherapy, cancer, PAF-related phospholipids, 119
Chlordiazepoxide
abuse liability of benzodiazepines, 255, 256, 257
repeated doses and psychomotor performance (table), 293
reversal of barbital withdrawal, 269
share of world market (table), 326
Chloroquine, blood versus plasma clearance, 6
Chromatin, 2,3,7,8-tetrachlorodibenzo-p-dioxin, 157
Circulation, hepatic clearance, model predictions, 19
Cirrhosis, experimental, plasma PAF, 119
Clearance
apparent, 2
approaches in pharmacology, 1
INDEX
blood versus plasma, 5
first-pass effect, 8
fractional, 2
intrinsic, 2, 14, 15, 37
in vitro-in vivo prediction, 33
metabolic, 2
organ, 2, 3
rate of elimination and, 7
total, 2
Clozapate, clofiazolam, and, share of world market (table), 326
Coagulation, blood versus plasma clearance, 6
Cocaine, abuse liability of benzodiazepines, 259
Corticosterone, benzodiazepine antagonist CGS-8216, 274
Criminals, use of benzodiazepines, 375
Cyclosporin, blood versus plasma clearance, 5
Dependence, withdrawal, benzodiazepines, 270
Desethylchloroquine, blood versus plasma clearance, 6
Diacetylglucol, platelet-activating factor, 102
Diazepam
absolute versus normalized clearance, 7
anxiety, 262
intermittent drug availability, 259
place preference in drug taking, 256, 257
psychomotor performance
insomnia (table), 296
elderly subjects (table), 298
repeated doses (table), 293
reinforcing effects, 265
self-administration, 258, 260
share of world market (table), 326
withdrawal signs (fig.), 272, 273
Dioxin: see 2,3,7,8-Tetrachlorodibenzo-p-dioxin
Dipotassium clorazepate, responding, 258
DNA, genomic elements, 2,3,7,8-tetrachlorodibenzo-p-dioxin, 154
Drug Abuse Warning Network, benzodiazepines, 382
Drug delivery
clearance and first-pass effect, 10
platelet-activating factor, 105
Drug distribution
blood versus plasma clearance, 5
clearance and first-pass effect, 9
Drug taking, drug seeking and, benzodiazepines, abuse liability, 254
Electrophysiology, opioid receptors, 213
Elimination
clearance approaches in pharmacology, 1
fractions, 31
hepatic
models (fig.), 13
site of drug administration (fig.), 9
in vitro-in vivo prediction, 33
rate, clearance and, 7
Endothelial cells
PAF-induced amplification cycle (fig.), 110
platelet-activating factor, 109
Endothelial-derived relaxant factor, cyclic GMP synthesis and function, 183
Epidemiology, benzodiazepine use and misuse, 320
Ergotamine, share of world market (table), 326
Escherichia coli, cyclic GMP synthesis and function, 183
Ethanol, reversing withdrawal, benzodiazepines, 268
Exercise, hepatic clearance, model predictions, 18
Flunitrazepam
psychomotor performance
effects of high doses (table), 292


INDEX

Kidney
  clearance and first-pass effect, 9
  clearance model, 27
  organ clearance, 2
  platelet-activating factor
  physiology and immune disorders, 114
  transplant rejection, 113

Learning, state-dependent, benzodiazepines, 305
Leslie, Frances M. Methods used for the study of opioid receptors, 197
Leukocytes, platelet-activating factor, 108
Lidocaine
  absolute versus normalized clearance, 7
  liver blood flow, 19
Life span, maximum potential, clearance and elimination, 37
Lignans
  chemical structures of PAF (fig.), 122
  PAF-antagonist activity (table), 125
Liver
  clearance and first-pass effect, 9, 10
  clearance model, 12
  organ clearance, 2
  uptake, bound drug, 24
Lorazepam
  absolute versus normalized clearance, 7
  insomnia, 261
  repeated doses and psychomotor performance (table), 293
  self-administration, 258
  share of world market (table), 326
Lung
  clearance and first-pass effect, 9
  organ clearance, 2

Mammals, clearance and elimination, 35
Mental retardation, drug use, 370
Meprobamate, share of world market (table), 326
Metabolites
  chemically reactive, 33
  clearance, 28
“fraction metabolized”, 29
Methadone, use of diazepam, 374
Methyl transferase, biosynthesis of platelet-activating factor, 102
Midazolam
  abuse liability of benzodiazepines, 255
  psychomotor performance and insomnia (table), 296
Models
  comparisons and discrimination, 26
  dispersion, 14
  distributed sinusoidal perfusion, 14
  hepatic clearance predictions, 15
  hepatic elimination (fig.), 13
  parallel-tube, 13
Murad, Ferid. See Waldman and Murad, 163
Muscle
  anoccygeus, catecholamine action, 64
  nonvascular, 86
  vascular, 85
Muscle, smooth
  airway, 80
  catecholamine action, 49, 50, 86
  cyclic GMP function, 187
  spike action, 59
  vascular, 66, 82
Myometrium, catecholamine action, 52, 81

Naloxone
  opioid receptor terminology, 199
2,3,7,8-Tetrachlorodibenzo-p-dioxin
formation (fig.), 148
gene expression regulation, 147
genomic elements (fig.), 154

Tetrahydrofuran derivatives, PAF antagonists, 121
Thermal stress, hepatic clearance, model predictions, 18
Thiols, regulation of guanylate cyclase, 176
Thrombosis, platelet participation, 109
Tomita, Tadeo. See Bültbring and Tomita, 49
Touqui, L. See Braquet et al., 97
Trachea, catecholamine action, 63
Tranquilizers
exposure of adult populations (table), 325
market share (table), 327
use among youth of three countries (table), 373
use by high school seniors (table), 372
Transmitter, release studies, opioid receptor, 212
Transplants, renal, rejection, platelet-activating factor, 113
Triazolam
abuse liability of benzodiazepines, 256, 257
alcohol withdrawal, 264
insomnia, 262
psychomotor performance
elderly subjects (table), 298
insomnia (table), 296
share of world market (table), 326
Triazolobenzodiazepines, PAF antagonism, 127

United Kingdom
benzodiazepine pattern of use, 358
hospital use of benzodiazepines, 340

United States
benzodiazepine pattern of use, 357
drug sales of benzodiazepines, 329
hospital use of benzodiazepines, 340
physician survey, 335
Ureter, catecholamine action on smooth muscle, 61

Vargaftig, B. B. See Braquet et al., 97
Vas deferens
catecholamine action on smooth muscle, 60
opioid receptor activity, 210

Vasodilators, cyclic GMP function, 187

Veins
catecholamine action, smooth muscle, 75
facial, 78
mesenteric, 76
saphenous, 76, 78

Verapamil, absolute versus normalized clearance, 7

Waldman, Scott A. and Murad Ferid. Cyclic GMP synthesis and function, 163

Warfarin, blood versus plasma clearance, 7
White blood cells, blood versus plasma clearance, 6
Whitlock, James P., Jr. The regulation of gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin, 147

Wilkinson, G. R. Clearance approaches in pharmacology, 1
Winger, Gail. See Woods et al., 251
Withdrawal
barbital, suppression, 269
self-selected subjects, benzodiazepines, 281
spontaneous and precipitated, benzodiazepines, 275
Woods, James H., Jonathan L. Katz, and Gail Winger. Abuse liability of benzodiazepines, 251

Xenobiotics
clearance and first-pass effect, 8
clearance approaches in pharmacology, 1
interspecies differences, 35

Zopiclone
alcohol withdrawal, 264
responding, 258